Overview

A Study of HS-10353 in Chinese Participants.

Status:
Enrolling by invitation

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10353 separately in Chinese healthy and major depressive disorder subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Hansoh Pharmaceutical Co., Ltd.